Search Results for "Drug Interactions"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug Interactions. Results 121 to 130 of 281 total matches.
Talazoparib (Talzenna) for Prostate Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
talazoparib.
DRUG INTERACTIONS – Talazoparib is a substrate
of the transporters P-glycoprotein (P-gp ...
The oral poly(ADP-ribose) polymerase (PARP)
inhibitor talazoparib (Talzenna – Pfizer) has been
approved by the FDA for use in combination with the
androgen receptor blocker enzalutamide (Xtandi) for
treatment of adults with homologous recombination
repair (HRR) gene-mutated metastatic castration-resistant
prostate cancer (mCRPC). The drug has
been available since 2018 for treatment of deleterious
or suspected deleterious germline BRCA-mutated
(gBRCAm), HER2-negative locally advanced or
metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 doi:10.58347/tml.2023.1682e | Show Introduction Hide Introduction
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
tolerability, minimize
toxicity and drug interactions, eliminate food or fluid
requirements, optimize ...
The FDA has approved Cabenuva (ViiV Healthcare),
an extended-release formulation of the new integrase
strand transfer inhibitor (INSTI) cabotegravir
copackaged with an extended-release formulation
of the non-nucleoside reverse transcriptase inhibitor
(NNRTI) rilpivirine, as a once-monthly complete
regimen for intramuscular (IM) treatment of adults
with HIV-1 infection who are virologically suppressed
(HIV-1 RNA...
Daprodustat (Jesduvroq) for Anemia of Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Feb 19, 2024 (Issue 1696)
in patients
with active malignancies.
DRUG INTERACTIONS — Daprodustat is primarily
metabolized by CYP2C8 ...
The FDA has approved daprodustat (Jesduvroq –
GSK), a hypoxia-inducible factor prolyl hydroxylase
inhibitor (HIF-PHI), for oral treatment of anemia due
to chronic kidney disease (CKD) in adults who have
been on dialysis for at least 4 months. It is the first
HIF-PHI and the first oral drug to be approved in the
US for this indication.
Med Lett Drugs Ther. 2024 Feb 19;66(1696):25-7 doi:10.58347/tml.2024.1696a | Show Introduction Hide Introduction
Rezafungin (Rezzayo) for Invasive Candida Infections
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024 (Issue 1705)
infant or
milk production.
DRUG INTERACTIONS ― Rezafungin is not a
substrate, inhibitor, or inducer ...
The FDA has approved rezafungin (Rezzayo – Cidara/Melinta), an intravenous echinocandin antifungal, for
once-weekly treatment of candidemia and invasive
candidiasis (IC) in adults with limited or no alternative
options. It is the first new drug to become available
in the US in more than 15 years for treatment of
systemic Candida infections.
Med Lett Drugs Ther. 2024 Jun 24;66(1705):101-4 doi:10.58347/tml.2024.1705d | Show Introduction Hide Introduction
Osilodrostat (Isturisa) for Cushing's Disease
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
inhibits several
steps in cortisol synthesis, is relatively inexpensive,
but it interacts with many drugs ...
The FDA has approved osilodrostat (Isturisa –
Recordati), a cortisol synthesis inhibitor, for oral
treatment of adults with Cushing's disease when
surgical resection of the pituitary adenoma is not an
option or has not been curative. Osilodrostat is the
first cortisol synthesis inhibitor to be approved in
the US for this indication. Other oral steroidogenesis
inhibitors such as ketoconazole and metyrapone have
been used off-label for this indication for many years.
Alpelisib (Vijoice) for PIK3CA-Related Overgrowth Spectrum (online only)
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022 (Issue 1663)
for
treatment of breast cancer.
DRUG INTERACTIONS ― Alpelisib is metabolized by
CYP3A4 and is a substrate ...
The oral kinase inhibitor alpelisib (Vijoice – Novartis)
has been approved by the FDA for treatment of
patients ≥2 years old with severe manifestations of
PIK3CA-related overgrowth spectrum (PROS) who
require systemic treatment. Alpelisib is the first
drug to be approved in the US for this indication.
It was also approved in 2019 as Piqray for use in
combination with fulvestrant for treatment of certain
types of breast cancer.
Tramadol Oral Solution (Qdolo) for Pain
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
frequently than with other opioids.3
DRUG INTERACTIONS — Patients taking CYP2D6
inhibitors with tramadol ...
The opioid agonist tramadol is now available in an oral
solution (Qdolo – Athena Bioscience) for management
of pain severe enough to require an opioid and for
which alternative treatment options are inadequate.
Tramadol has been available for years in immediate-release
tablets and capsules, extended-release
capsules (Ultram, and others), and in a fixed-dose
combination tablet with acetaminophen (Ultracet,
and generics).
Epcoritamab (Epkinly) for Diffuse Large B-Cell Lymphoma (DLBCL) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 12, 2023 (Issue 1678)
, including ICANS, serious
infections, and cytopenias were reported.
DRUG INTERACTIONS — Epcoritamab causes ...
Epcoritamab-bysp (Epkinly – Genmab), a bispecific
CD20-directed CD3 T-cell engager, has received
accelerated approval from the FDA for subcutaneous
treatment of relapsed or refractory diffuse large
B-cell lymphoma (DLBCL), not otherwise specified,
including DLBCL arising from indolent lymphoma,
and high-grade B-cell lymphoma after ≥2 lines
of systemic therapy. Epcoritamab is the second
T-cell-engaging bispecific antibody to become
available in the US for treatment of non-Hodgkin's
lymphoma; mosunetuzumab-axgb (Lunsumio) was
recently approved for relapsed or refractory...
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e103-4 doi:10.58347/tml.2023.1678d | Show Introduction Hide Introduction
Enfortumab Vedotin (Padcev) for Urothelial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • May 22, 2023 (Issue 1677)
these reactions
or who have other recurrent grade 3 or grade 4
skin reactions.
DRUG INTERACTIONS — Concomitant ...
Enfortumab vedotin-ejfv (Padcev – Astellas), a
nectin-4-directed antibody and microtubule inhibitor
conjugate, has received accelerated approval
from the FDA for use with the immune checkpoint
inhibitor pembrolizumab (Keytruda) for treatment
of locally advanced or metastatic urothelial cancer
in adults who are ineligible for cisplatin-containing
chemotherapy. Accelerated approval was based on
tumor response rates and the durability of response.
Med Lett Drugs Ther. 2023 May 22;65(1677):e91-2 doi:10.58347/tml.2023.1677g | Show Introduction Hide Introduction
Talquetamab (Talvey) for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
should be monitored before starting
talquetamab and periodically thereafter.
DRUG INTERACTIONS ...
Talquetamab-tgvs (Talvey – Janssen), a bispecific
GPRC5D-directed T-cell engager, has been granted
accelerated approval by the FDA for treatment of
relapsed or refractory multiple myeloma in adults
who received ≥4 prior lines of therapy, including a
proteasome inhibitor, an immunomodulatory drug,
and an anti-CD38 monoclonal antibody. Accelerated
approval was based on the response rate and
durability of response. Talquetamab is the first
bispecific GPRC5D-directed T-cell engager to be
approved in the US
Med Lett Drugs Ther. 2023 Sep 4;65(1684):e149-50 doi:10.58347/tml.2023.1684e | Show Introduction Hide Introduction